Precision management of atorvastatin: Cross-sectional analysis of genetic polymorphisms
This study successfully developed and validated a straightforward and reliable LC-MS/MS method for quantifying atorvastatin levels in human plasma. Significant CYP2D64 - atorvastatin links highlight the value of pharmacogenetic dosing. Integrating pharmacogenetics - especially in the Jordanian population - may enhance the safety, efficacy, and individualization of atorvastatin therapy.
Authors
- Eyad Mallah (ORCID: https://orcid.org/0000-0003-4794-954X)
- Muwafaq A. Al Hyari
- Tawfiq Arafat (ORCID: https://orcid.org/0000-0002-8483-6985)
- Kenza Mansoor (ORCID: https://orcid.org/0000-0002-8171-2055)
- Khaled W. Omari (ORCID: https://orcid.org/0000-0002-3089-2893)
- Amjad Shdifat
- Ahmad Abu Awaad
- Razan Ibrahim
- Luay Abu-Qatouseh
- Mohanad Odeh
- Mohammad I. A. Ahmad
Institutions
- Al-Ahliyya Amman University (JO)
- Hashemite University (JO)
- Jordan Hospital (JO)
- American University of the Middle East (KW)
- Petra University (JO)
- Jerash University (JO)
Publication Details
- Journal
- Advances in Clinical and Experimental Medicine
- Published
- 2026-01-05
- DOI
- https://doi.org/10.17219/acem/203504
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00